ALK PROTAC Degraders for Overcoming Kinase Inhibitor Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Drug resistance to ALK kinase inhibitors remains a significant obstacle in treating ALK mutant-positive non-small cell lung cancer, despite the development of newer generation inhibitors, necessitating the need for new drug strategies to overcome resistance mechanisms.
Innovation Solution
Development of compounds utilizing Proteolysis Targeting Chimeras (PROTAC) technology, which covalently connect ALK tyrosine kinase inhibitors to a VHL or CRBN protease ligand, forming a complex that ubiquitinates and degrades the ALK kinase, thereby overcoming resistance.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ALK kinase inhibitors are used to treat ALK mutant-positive non-small cell lung cancer, then treatment efficacy is improved, but drug resistance develops over time
Solution Approach 1:
Instead of inhibiting ALK kinase activity (the conventional approach), the patent inverts the strategy by promoting degradation of the ALK protein itself through PROTAC technology. This fundamental inversion bypasses the resistance mechanisms that develop against kinase inhibitors, as the protein is eliminated rather than blocked, resolving the contradiction between initial efficacy and long-term durability of response
Solution Approach 2:
The patent changes the therapeutic parameter from kinase inhibition to protein degradation. By using bifunctional PROTAC molecules that recruit E3 ubiquitin ligases (VHL or CRBN) to ubiquitinate and degrade ALK protein, the mechanism shifts from reversible enzymatic inhibition to irreversible protein elimination, thereby overcoming resistance and extending treatment duration
2Reliability
If newer generation ALK kinase inhibitors are developed to overcome resistance, then treatment efficacy is maintained, but the complexity of treatment regimens increases
Solution Approach 1:
The PROTAC compounds described in the patent possess universal activity against multiple ALK mutation types (including L1196M, L1152R, C1156Y, and others) through a single degradation mechanism. This multi-functional approach eliminates the need for sequential switching between different generations of kinase inhibitors, thereby reducing treatment complexity while maintaining efficacy across diverse resistance scenarios
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PROTAC compounds effectively degrade ALK tyrosine kinases, reducing their activity and stability, offering a potential solution to drug resistance and enhancing treatment efficacy in ALK mutant-positive cancers.
Implementation Method 1
forming a complex that ubiquitinates and degrades the ALK kinase
Implementation Method 2
ubiquitinates and degrades the ALK kinase
Data Source
Figure 1~2
Figure 3~4
Figure 5
AI summary
A compound of formula (I) and its antitumor application are disclosed. The compounds of formula (I) have degradation and inhibitory effects on ALK target proteins. They are mainly composed of four parts: the first part, ALK-TKI, being compounds with ALK tyrosine kinase inhibitory activity; the second part, LIN, being different kinds of linker (Linker); the third part, the ULM, being a small molecule ligand (ULM, ubiquitin ligase binding moiety) with ubiquitination of VHL, CRBN or other proteases; and the fourth part, the group A, being a carbonyl group or absent, which covalently bond ALK-TKI to LIN, wherein LIN and ULM are covalently bonded. A series of compounds designed and synthesized by the present disclosure have wide pharmacological activities, have functions of degrading ALK protein and inhibiting ALK activity, and can be used for related tumor treatment.